Clinical outcomes after spontaneous and nucleos(t)ide analogues (NUCs)-treated hepatitis B surface antigen(HBsAg) seroclearance in chronic HBV infection are favourable
AASLD LiverLearning®. Li X. Nov 14, 2016; 144719
Label: Hepatitis B: Epidemiology & Natural History
Mr. Xiang-Yong Li
Mr. Xiang-Yong Li
Login now to access Regular content available to all registered users.

AASLD Members enjoy free LiverLearning® Premium Access. Registrants of The Liver Meeting® receive LiverLearning® Premium Access for one year from the first day of the meeting. A LiverLearning® Subscription ($150.00 US) grants access to LiverLearning® Premium content for one year after date of purchase. Click here to purchase your Premium Access Subscription now.


Abstract
Discussion Forum (0)
Rate & Comment (0)
ABSTRACT FINAL ID: 1827

TITLE: Clinical outcomes after spontaneous and nucleos(t)ide analogues (NUCs)-treated hepatitis B surface antigen(HBsAg) seroclearance in chronic HBV infection are favourable

SPONSORSHIP - THIS STUDY WAS SPONSORED BY: (IF THIS ABSTRACT WAS NOT SPONSORED PLEASE INDICATE):
12th Five-Year science and technology major projects,NO.2012ZX10004-902

ABSTRACT BODY:
Objects To investigate the long-term clinical outcomes and durability of HBsAg seroclearance following nucleos(t)ide analogue (NUC) therapy or without antiviral treatment in patients with chronic HBV infection.
Methods we retrospectively analyzed 9335 patients with chronic HBV infection who was treated with nucleos(t)ide analogues or without antiviral treatment during a median follow-up period of 6.3 years, and a total of 158 patients achieved HBsAg seroclearance.
Results During follow-up for 2620 CHB patients who didn’t receive antiviral treatment, 54 patients acquired HBsAg seroclearance. The average time for acquiring HBsAg seroclearance was 5.5 (0~20) years. 16 cases of whom acquired HBsAg/HBsAb seroconversion, one patient returned HBsAg positive. HBeAg seroclearance in HBeAg-postive patients occured in 9 patients, and the rate of HBeAg/HBeAb seroconversion was 57.1% (8/14). The virological breakthrough was occurred in one patient (1.9%). None developed into liver cirrhosis, liver carcinoma or died. During follow-up for 6715 CHB patients who received NUC treatment, 104 patients acquired HBsAg seroclearance. The average time for acquiring HBsAg seroclearance was 6.6 (0.5~14) years. HBsAg seroconversion occured in 29 patients, and one patients returned HBsAg positive. The rate of HBeAg seroclearance was 88.2%(30/34), and HBeAg/HBeAb seroconversion occured in 27 patients. No patient developed virological breakthrough. There were 28 cases discontinued the NUCs treatment. 3 cases of 104 patients with HBsAg seroclearance got disease progression, 1 case developed into compensated cirrhosis from the initial imaging diagnosis of CHB, and 2 cases developed into liver carcinoma from the initial diagnosis of decompensated liver cirrhosis; no death occurred among the patients.
Conclusion HBsAg seroclearance in chronic HBV infection with or without antiviral treatment was associated with favourable clinical outcomes in most cases during long-term follow-up.
Code of conduct/disclaimer available in General Terms & Conditions